Open
Do other lipid agents improve neuropathy, eye & foot versus placebo?
Mostly studied in type 2 & unspecified diabetes.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 0
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 4
- With posted results
- 1
- Published papers
- 0
Of 3 decided analyses: 1 favor other lipid agents, 2 find no difference, 0 favor the comparator.
Trials
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye StudyNCT00542178 · 9 posted results
- Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized TrialNCT00923676
- Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical TrialNCT02129231
- Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic PatientsNCT04140201